Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: Effects on lipid metabolism

Contraception

Volumn 84, Issue 2, 2011, Pages 155-159

  Barreiros, Fernando Augusto ^a   Guazzelli, Cristina Aparecida Falbo ^a   Barbosa, Ricardo ^a   Torloni, Maria Regina ^a   Barbieri, Marcia ^a   Araujo, Fabio F ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Combined contraceptives; Continuous; Contraceptive vaginal ring; Extended cycle; Metabolic change; Vaginal hormonal contraception

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ETHINYLESTRADIOL; ETONOGESTREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BIRTH CONTROL; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG RELEASE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; VAGINA CONTRACEPTION; VAGINA RING;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79960324695     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.11.002     Document Type: Article

References (33)

1. Stadel B.V. Oral contraceptives and cardiovascular diseases (first of two parts) N Engl J Med 305 1981 612 619
2. Stadel B.V. Oral contraceptives and cardiovascular diseases (second of two parts) N Engl J Med 305 1981 672 677 (Pubitemid 11056136)
3. Sarewski A., and Mansour D. The "pill scare": the responses of authorities, doctors and patients using oral contraception Hum Reprod Update 5 1999 627 632 (Pubitemid 30034885)
4. Conard J. Biological coagulation findings in third-generation oral contraceptives Hum Reprod Update 5 1999 672 680 (Pubitemid 30034890)
5. Edwards R.G., and Cohen J. The recent saga of cardiovascular disease and safety of oral contraceptives Hum Reprod Update 5 1999 565 620 (Pubitemid 30034883)
6. Godsland I., Crook D., and Simpson R. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism N Engl J Med 323 1990 1375 1381
7. Teichmann A. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel Int J Fertil Menopausal Stud 40 1995 98 104
8. Sulak P., Lippman J., Siu C., Massaro J., and Godwin A. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinylestradiol. Cycle control, lipid effects, and user satisfaction Contraception 59 1999 161 166 (Pubitemid 29277545)
9. Davies M.J., and Wolf N. Atherosclerosis: what is it and why does it occur? Br Heart J 69 1993 53 59
10. Wiseman R.A., and Macrae K.E. Oral contraceptives and the decline in mortality form circulatory disease Fertil Steril 35 1981 277 283 (Pubitemid 11146964)
11. Sturdevant F.M. Safety of oral contraceptives related to steroid content: a critical review Int J Fertil 34 1989 323 332
12. Realini J.P., and Goldzieher J.W. Oral contraceptives and cardiovascular disease: a critique to the epidemiologic studies Am J Obstet Gynecol 152 1985 729 798 (Pubitemid 15015107)
13. Szarewski A. High acceptability and satisfaction with NuvaRing use Eur J Contracept Reprod Health Care 7 Suppl 2 2002 31 36 (Pubitemid 36269618)
14. FDA approves NuvaRing contraceptive implant J Gend Specif Med 5 2 2002 6
15. World Health Organization Medical eligibility criteria for contraceptive use. Reproductive heath and research 4th ed. 2009 WHO Geneva
16. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
17. Barreiros F.A., Guazzelli C.A., Barbosa R., de Assis F., and de Araújo F. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects Contraception 81 2010 223 225
18. Tuppurainen M., Klimscheffskij R., Venhola M., and Dieben T.O. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study Contraception 69 2004 -9
19. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033 (Pubitemid 34084825)
20. van der Steeg W.A., Holme I., and Boekholdt S.M. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 51 2008 634 642 (Pubitemid 351186873)
21. Akerlund M., Almström E., Högstedt S., and Nabrink M. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone Acta Obstet Gynecol Scand 73 1994 136 143 (Pubitemid 24064088)
22. Walldius G., and Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid modifying therapy J Intern Med 255 2004 188 205 (Pubitemid 38241363)
23. Barter P.J., Ballantyne C.M., and Carmena R. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel Intern Med 259 2006 247 258
24. McQueen M.J., Hawken S., and Wang X. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Comment Lancet 372 2008 185 186
25. Porkka K.V.K., Erkkola R., Taimela S., Raitakari O.T., Dahlen G.H., and Viikari J.S.A. Influence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors Ann Med 27 1995 193 198
26. Crook D., Godsland I.F., and Wynn V. Oral contraception and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins Am J Obstet Gynecol 158 1988 1612 1620
27. Crook D. Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin Contraception 55 1997 219 224 (Pubitemid 27435167)
28. Elkind-Hirsch K.E., Darensbourg C., Ogden B., Ogden L.F., and Hindelang P. Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive Contraception 76 2007 348 356 (Pubitemid 47600125)
29. Sitruk-Ware R.L., Menard J., and Rad M. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen Contraception 75 2007 430 437 (Pubitemid 46764302)
30. Lopez L.M., Grimes D.A., and Schulz K.F. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus Cochrane Database Syst Rev 7 2009 CD006133 Review
31. Machado R.B., Fabrini P., Cruz A.M., Maia E., and Bastos A.C. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg) Contraception 70 2004 365 370 (Pubitemid 39422512)
32. Machado R.B., de Melo N.R., Maia H. Jr, and Cruz A.M. Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles Contraception 81 2010 102 106
33. Wiegratz I., Stahlberg S., and Manthey T. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use Contraception 81 2010 57 61